Table 5.
QLQ-C30 and QLQ-BR23 scales distribution at baseline and changes from baseline to intermediate time in patients having CIRS ≥5 and CIRS <5. Variable distributions are described by median and IQR.
| Baseline (T0) | Changes from baseline (T0) to intermediate (T1) | |||||
|---|---|---|---|---|---|---|
| CIRS ≥5 | CIRS <5 | p # | CIRS ≥5 | CIRS <5 | p $ | |
| QLQ-C30 Functional Scales | ||||||
| Physical | 93.33 (76.67–93.33) | 86.67 (80–100) | 0.7996 | −6.66 (−6.67 to 6.67) | 0 (−6.67 to 4.96) | 0.7657 |
| Role | 83.33 (66.67–100) | 83.33 (83.33–100) | 0.6103 | 0 (−16.66 to 8.33) | 0 (0–0) | 0.9691 |
| Emotional | 75 (75–91.67) | 83.33 (75–91.67) | 0.3413 | 8.33 (−4.17 to 12.5) | 0 (−8.33 to 8.34) | 0.9857 |
| Cognitive | 100 (91.67–100) | 100 (87.5–100) | 0.8001 | 0 (−8.34 to 0) | 0 (0–0) | 0.9386 |
| Social | 83.33 (66.67–100) | 100 (70.84–100) | 0.1728 | 0 (0–16.66) | 0 (0–0) | 0.3544 |
| QLQ-C30 Symptoms | ||||||
| Fatigue | 33.33 (22.22–38.89) | 22.22 (11.11–44.44) | 0.3908 | −11.11 (−16.67 to 11.11) | −5.55 (−11.11 to 11.11) | 0.8284 |
| Nausea and vomiting | 0 (0–0) | 0 (0–0) | 0.1818 | 0 (0–0) | 0 (0–0) | 0.6931 |
| Pain | 0 (0–16.67) | 0 (0–33.33) | 0.4479 | 0 (0–16.66) | 0 (−12.5 to 0) | 0.0539 |
| Dyspnoea | 0 (0–0) | 0 (0–25) | 0.6525 | 0 (0–0) | 0 (0–0) | 0.5572 |
| Insomnia | 33.33 (0–33.33) | 0 (0–33.33) | 0.3598 | 0 (−33.33 to 0) | 0 (−24.99 to 0) | 0.9614 |
| Appetite loss | 0 (0–16.67) | 0 (0–0) | 0.0610 | 0 (0–0) | 0 (0–0) | 0.0908 |
| Constipation | 0 (0–33.33) | 0 (0–0) | 0.0456 | 0 (−33.33–0) | 0 (0–0) | 0.1472 |
| Diarrhoea | 0 (0–0) | 0 (0–0) | 0.4662 | 0 (0–0) | 0 (0–0) | 0.8277 |
| Financial difficulties | 0 (0–0) | 0 (0–0) | 0.5938 | 0 (0–0) | 0 (0–0) | 0.1023 |
| QLQ-C30 Global Health Status | 133.33 (116.67–141.67) | 133.33 (116.67–150) | 0.6100 | 0 (0−16.67) | 0 (0–16.66) | 0.3910 |
| QLQ-C30 Final scoring | 86.62 (81.01–91.37) | 94.73 (82.36–97.59) | 0.0909 | 1.62 (−3.94 to 7.01) | 0.77 (−1.14 to 2.86) | 0.6183 |
| QLQ-BR23 Functional Scales | ||||||
| Body image | 95.83 (66.67–100) | 91.67 (68.76–100) | 0.9687 | 0 (0–8.34) | 0 (−6.25 to 0) | 0.3297 |
| Future perspective | 66.67 (33.33–66.67) | 66.67 (33.33–100) | 0.5593 | 0 (−33.33 to 33.33) | 0 (−33.33 to 33.33) | 0.7471 |
| Sexual functioning | 0 (0–33.33) | 0 (0–33.33) | 0.5104 | 0 (0–0) | 0 (0–0) | 0.6379 |
| Sexual enjoyment | 0 (0–33.33) | 0 (0–33.33) | 0.7812 | 0 (0–0) | 0 (0–0) | 0.2401 |
| QLQ-BR23 Symptoms | ||||||
| Systemic therapy side-effects | 9.52 (0–19.05) | 0 (0–9.52) | 0.0691 | 4.76 (−4.76 to 9.53) | 4.76 (0–9.52) | 0.6029 |
| Upset by hair loss | 0 (0–0) | 0 (0–0) | 0.9903 | 0 (0–0) | 0 (0–0) | 0.9431 |
| Arm symptoms | 0 (0–5.56) | 0 (0–11.11) | 0.7788 | 0 (0–5.56) | 0 (0–0) | 0.3825 |
| Breast symptoms | 0 (0–0) | 0 (0–8.33) | 0.0631 | 0 (0–0) | 0 (0–0) | 0.5431 |
#
p value from the Mann-Whitney test;
$
p value from the Wilcoxon test for paired samples.
CIRS, Cumulative Illness Rating Scale; QLQ-BR23, Quality of Life Questionnaire Breast Cancer Questionnaire; QLQ-C30, Quality of Life Questionnaire CORE 30.